Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities    
Net loss $ (4,093,113) $ (9,924,029)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation 316,689 952,828
Depreciation and amortization 187,444 190,917
Loss on disposal of fixed assets 53,609 (7,595)
Amortization of right-of-use assets 113,029 122,353
Changes in operating assets and liabilities    
Prepaid insurance, other prepaid expenses and current assets 211,375 (103,760)
Security deposit 22,432 (19,600)
Accounts payable 244,012 427,530
Accrued expenses and other current liabilities (390,446) 289,507
Operating lease liability (112,942) (120,564)
Net cash used in operating activities (3,447,911) (8,192,413)
Cash flows from investing activities    
Purchase of laboratory and office equipment (13,447) (148,411)
Proceeds received on sale of equipment 8,500 0
Net cash used in investing activities (4,947) (148,411)
Cash flows from financing activities    
Principal payment of finance lease liability (29,171) (27,120)
Payment of issuance costs for equity commitment (59,973) 0
Proceeds from exercise of stock options 721 0
Net cash used in financing activities (88,423) (27,120)
Net decrease in cash and cash equivalents (3,541,281) (8,367,944)
Cash and cash equivalents, beginning of period 17,386,326 47,326,060
Cash and cash equivalents, end of period 13,845,045 38,958,116
Non-cash investing and financing activities:    
Purchases of laboratory and office equipment in accounts payable 13,447 0
Right-of-use asset obtained in exchange for operating lease liabilities $ 0 $ 164,613